foslevodopa
Trade name: VYALEV
Small moleculeapprovedOrphan Drug FDA
Approved
Oct 16, 2024
Clinical trial activity
0 trials · 0 clinical orgs · 1 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Timeline
Indications
Approved for
Mechanism of action
- Beta-1 adrenergic receptorAGONIST
Beta-1 adrenergic receptor agonist
- Dopamine receptorAGONIST
Dopamine receptor agonist
Combination products
vyalev
with foscarbidopa
Approval history
- approvedOct 16, 2024
Chemistry & pharmacology
Loading structure…
SMILES
N[C@@H](Cc1ccc(OP(=O)(O)O)c(O)c1)C(=O)O- Mol. weight
- 277.17 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL4594379 ↗
Organizations
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| AbbVie | For profit | NDA | Oct 16, 2024 |